4. Sanofi-Aventis and Oxford BioMedica

Who: Sanofi-Aventis
With: Oxford BioMedica
What: $690 million licensing deal

Summary: Sanofi-Aventis hopped on the cancer vaccine bandwagon when it inked a $690 million licensing deal for Oxford BioMedica's TroVax. Oxford BioMedica is slated to get $39 million up front and $25 million payments as targets are hit. The deal includes additional payments if TroVax goes on to win approval for multiple indications--TroVax is currently in Phase III for renal cancer, but the company is exploring its utility in a range of cancers including colorectal, lung, breast and prostate cancer. The Sanofi/Oxford BioMedica pact is an example of big pharma's interest in cancer vaccines. Release

Related Articles:
Sanofi inks $690M pact for cancer vaccine. Report
Cancer vaccine market to soar. Report
Oxford BioMedica says licensing talks heating up. Report
Oxford BioMedica touts mid-stage TroVax trial data. Report

4. Sanofi-Aventis and Oxford BioMedica

Suggested Articles

Robertson, M.D., who led global development teams within Shire’s neuroscience division, is now Yumanity Therapeutics’ chief medical officer.

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.